CR8544A - Compuestos de quinolina sustituidos - Google Patents
Compuestos de quinolina sustituidosInfo
- Publication number
- CR8544A CR8544A CR8544A CR8544A CR8544A CR 8544 A CR8544 A CR 8544A CR 8544 A CR8544 A CR 8544A CR 8544 A CR8544 A CR 8544A CR 8544 A CR8544 A CR 8544A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- substituted quinoline
- quinoline compounds
- compositions
- mtp
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000018616 Apolipoproteins B Human genes 0.000 abstract 1
- 108010027006 Apolipoproteins B Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
Esta invencion se refiere a inhibidores de la secrecion de MTP/Apo-B de Formula (I) donde R1-R7, X1 m, y n son como se ha definido en la memoria descriptiva, asi como a composiciones farmaceuticas que comprenden los compuestos, y a procedimientos de uso de los compuestos y composiciones. Los compuestos de la invencion son utiles en el tratamiento de la obesidad y enfermedades,afecciones o trastornos asociados.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54167804P | 2004-02-04 | 2004-02-04 | |
| US63376304P | 2004-12-06 | 2004-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR8544A true CR8544A (es) | 2006-11-30 |
Family
ID=34890449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR8544A CR8544A (es) | 2004-02-04 | 2006-08-03 | Compuestos de quinolina sustituidos |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US7468378B2 (es) |
| EP (1) | EP1716137A1 (es) |
| JP (1) | JP2007520543A (es) |
| KR (1) | KR100799802B1 (es) |
| AP (1) | AP2006003685A0 (es) |
| AR (1) | AR047529A1 (es) |
| AU (1) | AU2005214159A1 (es) |
| BR (1) | BRPI0507462A (es) |
| CA (1) | CA2555133A1 (es) |
| CO (1) | CO5700721A2 (es) |
| CR (1) | CR8544A (es) |
| EA (1) | EA010369B1 (es) |
| EC (1) | ECSP066717A (es) |
| GE (1) | GEP20084360B (es) |
| IL (2) | IL176715A0 (es) |
| MA (1) | MA28347A1 (es) |
| NL (1) | NL1028192C2 (es) |
| NO (1) | NO20063928L (es) |
| OA (1) | OA13365A (es) |
| PA (1) | PA8623001A1 (es) |
| PE (1) | PE20050773A1 (es) |
| SV (1) | SV2007002007A (es) |
| TW (2) | TW200906800A (es) |
| UY (1) | UY28734A1 (es) |
| WO (1) | WO2005080373A1 (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105820160B (zh) | 2003-11-05 | 2019-02-12 | 萨可德生物科学公司 | 细胞粘着调节剂 |
| CA2555133A1 (en) * | 2004-02-04 | 2005-09-01 | Pfizer Products Inc. | Substituted quinoline compounds |
| US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| EP1740553A1 (en) * | 2004-04-14 | 2007-01-10 | AstraZeneca AB | Aryl glycinamide derivatives and their use as nk1 antagonists and serotonin reuptake inhibithors |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| NZ563009A (en) | 2005-04-19 | 2011-05-27 | Surface Logix Inc | Inhibitors of microsomal triglyceride transfer protein and Apo-B secretion |
| EP2222631B1 (en) * | 2006-10-23 | 2011-08-17 | Pfizer Inc. | Substituted phenylmethyl bicyclocarboxyamide compounds |
| JP2010509392A (ja) | 2006-11-13 | 2010-03-25 | ファイザー・プロダクツ・インク | ジアリール、ジピリジニルおよびアリール−ピリジニル誘導体ならびにその使用 |
| WO2008097471A1 (en) * | 2007-02-02 | 2008-08-14 | Shivvers Steve D | High efficiency drier with multi stage heating and drying zones |
| WO2008100423A1 (en) * | 2007-02-09 | 2008-08-21 | Sirtris Pharmaceuticals, Inc. | Gut microsomal triglyceride transport protein inhibitors |
| WO2009014674A1 (en) * | 2007-07-23 | 2009-01-29 | Sirtris Pharmaceuticals, Inc. | Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors |
| EP2214481B1 (en) | 2007-10-15 | 2019-05-01 | United Animal Health, Inc. | Method for increasing performance of offspring |
| CA2702984C (en) * | 2007-10-19 | 2017-04-11 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
| WO2010018547A1 (en) * | 2008-08-13 | 2010-02-18 | Pfizer Inc. | Aminoquinoline compounds |
| EP2723717A2 (en) | 2011-06-24 | 2014-04-30 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
| AU2012272898A1 (en) | 2011-06-24 | 2013-04-11 | Amgen Inc. | TRPM8 antagonists and their use in treatments |
| KR101979042B1 (ko) * | 2011-08-04 | 2019-05-15 | 어레이 바이오파마 인크. | 세린/트레오닌 키나제 억제제로서의 퀴나졸린 화합물 |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| US9624172B2 (en) | 2014-02-17 | 2017-04-18 | Hetero Research Foundation | Polymorphs of lomitapide and its salts |
| EP3798214B1 (en) | 2014-10-06 | 2022-09-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2016055934A1 (en) * | 2014-10-09 | 2016-04-14 | Glenmark Pharmaceuticals Limited | Amorphous form of lomitapide mesylate |
| EP3436446B1 (en) | 2016-03-31 | 2023-06-07 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| SG10201913595YA (en) | 2016-09-30 | 2020-02-27 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| MA49235B1 (fr) | 2016-12-09 | 2021-02-26 | Vertex Pharma | Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur |
| EP3634402B1 (en) | 2017-06-08 | 2026-01-21 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2018228452A1 (zh) * | 2017-06-16 | 2018-12-20 | 成都先导药物开发有限公司 | 一种抑制 rock 的化合物及其用途 |
| BR112020000941A2 (pt) | 2017-07-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| TWI799435B (zh) | 2017-08-02 | 2023-04-21 | 美商維泰克斯製藥公司 | 製備化合物之製程 |
| IL273831B2 (en) | 2017-10-19 | 2024-10-01 | Vertex Pharma | Crystalline forms and compositions of cftr modulators |
| CN111757874B (zh) | 2017-12-08 | 2024-03-08 | 弗特克斯药品有限公司 | 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2819039A1 (de) | 1978-04-29 | 1979-11-08 | Bayer Ag | Leimungsmittel fuer papier |
| MC1454A1 (fr) | 1981-03-11 | 1983-02-01 | Wellcome Found | Composes biaryliques substitues,leur preparation et preparation de medicaments contenant ces composes |
| EP0580860B2 (en) | 1991-04-16 | 2004-12-15 | Nippon Shinyaku Company, Limited | Method of manufacturing solid dispersion |
| HU218419B (hu) | 1992-03-06 | 2000-08-28 | E.R. Squibb And Sons, Inc. | Mikroszomális triglicerid transzfer protein (MTP) nagy molekulatömegű alegységének rekombináns úton történő előállítására és a protein és inhibitorainak kimutatására szolgáló eljárások |
| US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| ES2227769T3 (es) | 1994-05-27 | 2005-04-01 | Glaxosmithkline S.P.A. | Derivados de quinolina como antagonistas del receptor nk3 de taquiquinina. |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| DE19519245C2 (de) * | 1995-04-14 | 2003-04-30 | Boehringer Ingelheim Kg | Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| EP0832069B1 (en) | 1995-06-07 | 2003-03-05 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
| MX9709914A (es) | 1995-06-07 | 1998-03-31 | Pfizer | Derivados de acido bifenil-2-carboxilico-tetrahidro-isoquinolin-6-ilo, su preparacion y el uso de los mismos. |
| US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| TR199802385T2 (xx) * | 1996-05-20 | 1999-04-21 | Darwin Discovery Limited | TNF inhibit�rleri ve FDE-IV inhibit�rleri olarak kinolin karboksamidler. |
| JP2000515501A (ja) | 1996-07-01 | 2000-11-21 | イーライ・リリー・アンド・カンパニー | 低血糖化および低脂血化用化合物群 |
| KR100217618B1 (ko) * | 1996-12-12 | 1999-09-01 | 정몽규 | 와셔액 분사위치 조절 장치 |
| WO1998027979A1 (en) | 1996-12-20 | 1998-07-02 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of microsomal triglyceride transfer protein and method |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| US5968950A (en) | 1997-06-23 | 1999-10-19 | Pfizer Inc | Apo B-secretion/MTP inhibitor hydrochloride salt |
| DE69837903T2 (de) | 1997-08-11 | 2008-02-14 | Pfizer Products Inc., Groton | Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit |
| AP1201A (en) | 1997-09-17 | 2003-09-01 | Smithkline Beecham Corp | Method for the synthesis of quinoline derivatives. |
| NZ505362A (en) * | 1997-12-22 | 2004-12-24 | Upjohn Co | 4-hydroxyquinoline-3-carboxamides and -hydrazides useful as antiviral agents |
| CO5090829A1 (es) | 1998-07-21 | 2001-10-30 | Novartis Ag | Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b. |
| IL139449A0 (en) | 1999-11-10 | 2001-11-25 | Pfizer Prod Inc | Use of apo b secretion/mtp inhibitors |
| CA2325358C (en) * | 1999-11-10 | 2005-08-02 | Pfizer Products Inc. | 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b |
| US20020032238A1 (en) * | 2000-07-08 | 2002-03-14 | Henning Priepke | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments |
| US6417367B1 (en) * | 2000-08-11 | 2002-07-09 | Pfizer Inc. | Methods of making quinoline amides |
| WO2002028835A1 (en) | 2000-10-05 | 2002-04-11 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide compounds as apo b secretion inhibitors |
| PL367680A1 (en) | 2001-06-28 | 2005-03-07 | Pfizer Products Inc. | Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion |
| HUP0700124A2 (en) | 2001-10-25 | 2007-06-28 | Takeda Chemical Industries Ltd | Quinoline compound |
| AU2002360489A1 (en) * | 2001-12-07 | 2003-06-23 | The Regents Of The University Of California | Treatment for age-related macular degeneration |
| US20030162788A1 (en) * | 2002-01-10 | 2003-08-28 | Boehringer Ingelheim Pharma Kg | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals |
| CN101838218A (zh) | 2002-02-28 | 2010-09-22 | 日本烟草产业株式会社 | 酯化合物及其医药用途 |
| BR0317426A (pt) * | 2002-12-20 | 2005-11-16 | Pfizer Prod Inc | Inibidores de proteìna de transferência de triglicéridos microssomais |
| WO2004056777A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Microsomal triglyceride transfer protein inhibitors |
| CA2555133A1 (en) * | 2004-02-04 | 2005-09-01 | Pfizer Products Inc. | Substituted quinoline compounds |
-
2005
- 2005-01-24 CA CA002555133A patent/CA2555133A1/en not_active Abandoned
- 2005-01-24 JP JP2006551942A patent/JP2007520543A/ja active Pending
- 2005-01-24 OA OA1200600247A patent/OA13365A/en unknown
- 2005-01-24 KR KR1020067015770A patent/KR100799802B1/ko not_active Expired - Fee Related
- 2005-01-24 GE GEAP20059563A patent/GEP20084360B/en unknown
- 2005-01-24 BR BRPI0507462-2A patent/BRPI0507462A/pt not_active IP Right Cessation
- 2005-01-24 EP EP05702327A patent/EP1716137A1/en not_active Withdrawn
- 2005-01-24 WO PCT/IB2005/000167 patent/WO2005080373A1/en not_active Ceased
- 2005-01-24 EA EA200601239A patent/EA010369B1/ru not_active IP Right Cessation
- 2005-01-24 AP AP2006003685A patent/AP2006003685A0/xx unknown
- 2005-01-24 AU AU2005214159A patent/AU2005214159A1/en not_active Abandoned
- 2005-02-02 AR ARP050100394A patent/AR047529A1/es not_active Application Discontinuation
- 2005-02-02 UY UY28734A patent/UY28734A1/es unknown
- 2005-02-02 PE PE2005000125A patent/PE20050773A1/es not_active Application Discontinuation
- 2005-02-03 US US11/049,852 patent/US7468378B2/en not_active Expired - Fee Related
- 2005-02-03 TW TW097141214A patent/TW200906800A/zh unknown
- 2005-02-03 TW TW094103301A patent/TWI306454B/zh not_active IP Right Cessation
- 2005-02-04 PA PA20058623001A patent/PA8623001A1/es unknown
- 2005-02-04 NL NL1028192A patent/NL1028192C2/nl not_active IP Right Cessation
- 2005-02-04 SV SV2005002007A patent/SV2007002007A/es not_active Application Discontinuation
-
2006
- 2006-06-15 US US11/424,488 patent/US7368573B2/en not_active Expired - Fee Related
- 2006-07-05 IL IL176715A patent/IL176715A0/en unknown
- 2006-07-21 EC EC2006006717A patent/ECSP066717A/es unknown
- 2006-07-28 CO CO06074303A patent/CO5700721A2/es not_active Application Discontinuation
- 2006-08-03 CR CR8544A patent/CR8544A/es not_active Application Discontinuation
- 2006-08-04 MA MA29241A patent/MA28347A1/fr unknown
- 2006-09-01 NO NO20063928A patent/NO20063928L/no not_active Application Discontinuation
- 2006-10-30 US US11/554,351 patent/US7393958B2/en not_active Expired - Fee Related
-
2010
- 2010-10-27 IL IL208963A patent/IL208963A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR8544A (es) | Compuestos de quinolina sustituidos | |
| CR9834A (es) | [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la ezquizofrenia | |
| CR8649A (es) | Derivados de formamidina para el tratamiento de enfermedades | |
| CR10304A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
| ECSP099413A (es) | COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO | |
| CY1109998T1 (el) | Ενδυναμωτες υποδοχεων γλουταμινικου | |
| UY29253A1 (es) | 3-amino-pirazol(3,4b)piridinas como inhibidores de proteintirosinquinasas, su preparación y uso como medicamento | |
| CR10060A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
| UY30748A1 (es) | Compuesto0s novedosos | |
| CR9223A (es) | 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen | |
| ECSP067121A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
| CR10497A (es) | Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38 | |
| ECSP067120A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
| UY29149A1 (es) | Tiazolil-dihidro-indazoles | |
| DOP2005000025A (es) | Compuestos de heteroaril- y fenilsulfamoilo sustituidos | |
| PA8627001A1 (es) | Compuestos para el tratamiento de enfermedades | |
| GT200500310A (es) | Compuestos organicos | |
| HN2003000104A (es) | Derivados de ciclopenteno | |
| DOP2006000024A (es) | Tiazolidinonas, su preparación y su uso como medicamento | |
| CR7735A (es) | Piperizinas heterociclicas sustituidas para el tratamiento de la esquizofrenia | |
| PA8657701A1 (es) | Derivado de quinolina, su uso, preparacion y medicamento que lo contiene | |
| DOP2005000015A (es) | Compuestos de quinolina sustituidos | |
| GT200500016A (es) | Compuestos de quinolina sustituidos | |
| CR8825A (es) | Metabolitos de indolilalquilamina como ligandos 5- hidroxitriptamina-6 | |
| DK1768945T3 (da) | Substituerede hydroxyacetophenon-derivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |